Spectrum Pharmaceuticals Inc

Spectrum Pharmaceuticals — Proxy Contest (June 2017)

10 slides from Spectrum Pharmaceuticals's proxy contest presentation, Jun 7, 2017

  1. Slide 1: Spectrum Pharmaceuticals June 2017

    Spectrum Pharmaceuticals June 2017

  2. Slide 2: Safe Harbor Statement

    2 Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management’s current b

  3. Slide 3: Spectrum is a Biotech Company Focused on Bringing Cancer Treatments to Patients in Need

     Spectrum currently markets six oncology/hematology products that target rare types of cancer such as advanced metastatic colorectal cancer, acute lymphoblastic leukemia, multiple myeloma and non-Hodgkin’s lymphoma  Spectrum is also in advanced stages of development with three new compounds  ROLO

  4. Slide 4: Spectrum has Been Successful at Acquiring and Advancing Drugs to Treat Cancer

    4 Spectrum has Been Successful at Acquiring and Advancing Drugs to Treat Cancer 2012 • Acquired Ex-U.S. rights to market Zevalin • In-licensed ROLONTIS • Acquired Allos Therapeutics 2013 • Re-acquired rights for Qapzola from Allergan • In-licensed Evomela • Acquired Talon Therapeutics • Filed Beleod

  5. Slide 5: Committed to Sound Corporate Governance

     All directors elected annually  Continuing changes to Governance Practices o Elected an independent Lead Director (Gino Lenaz) o Adopted Corporate Governance Guidelines o Adopted Stock Ownership Policy o Adopted Anti-Hedging Policy o Amended our 2009 Incentive Award Plan to prohibit recycling or

  6. Slide 6: Long Term Incentive Compensation Program Revamped in 2017

    6 Long Term Incentive Compensation Program Revamped in 2017 • In 2016, the Compensation Committee undertook a comprehensive review of the Company’s executive compensation practices • The new program was designed based on, benchmarking versus peers, feedback from shareholders, advice from an independ

  7. Slide 7: 2016 Peer Group

    7 2016 Peer Group AMAG Pharmaceuticals, Inc. Albany Molecular Research Inc. Genomic Health Inc. Luminex Corporation Amphastar Pharmaceuticals, Inc. Mimedx Group, Inc. Pernix Therapeutics Holdings, Inc. SciClone Pharmaceuticals Inc. Supernus Pharmaceuticals, Inc. Halozyme Therapeutics, Inc. Sucampo P

  8. Slide 8: Compensation Plan Structure

    8 Compensation Plan Structure Base Salary • To attract and retain talent in a highly competitive labor market • Based on pay levels of comparable positions within peer group, as well as qualifications, experience and role characteristics • Merit increases based on individual performance and size of

  9. Slide 9: CEO Compensation Overview

    CEO Compensation Overview a Realized Pay

  10. Slide 10: We Seek Your Support at Our Annual Meeting

    10 We Seek Your Support at Our Annual Meeting 2016 Spectrum Pharmaceuticals Management Recommendations  FOR Election of Directors  FOR Advisory vote to approve the compensation of our named executive officers  FOR every three years to conduct an advisory vote to approve the compensation of our na

Spectrum Pharmaceuticals — Proxy Contest (June 2017) on 6ix